TRU: AI-driven cervical cancer screening device posts rapid sales growth and global expansion

About this update from Truscreen Group Ltd.

AI-powered cervical cancer screening device achieved 42% sales growth in FY26, with over 1 million women screened globally and strong clinical validation. Focused on LMICs, the company leverages partnerships and a recurring revenue model to capture a growing share of the $7.9bn market.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Truscreen Group Ltd.